­Sent by email to: [xxxxxxxxxxx.xxxxxxxxxxx](mailto:christopher.kiff@bms.com)

XX XXXX XXXXX

Xxxxxxxxx Xxxxxxxx, Xxxxxx Xxxxxx xxx Xxxxxxxx Xxxxxxx

Bristol-Myers Squibb Pharmaceuticals Limited

Uxbridge Business Park

Sanderson Road

Uxbridge, Middlesex

UB8 1DH

23 October 2020

Dear Xx Xxxxx

**Final Appraisal Document - Nivolumab for previously treated locally advanced or metastatic non-squamous non-small-cell (NSQ NSCLC) lung cancer [ID1572] (CDF review TA848)**

Thank you for your letter of 22 October.  In light of its content I agree the initial scrutiny letter should stand as the final decision on scrutiny.

I note and understand your points about the appeal hearing and the continuing importance of the individual points of appeal.  I am sure the appeal panel chair will take these points into account in deciding how best to make use of the hearing time.

Yours sincerely

Tim Irish

Vice Chair

National Institute for Health and Care Excellence